Seaport Research initiated coverage of Xylem with a Neutral rating and no price target. The recent Evoqua acquisition should be accretive to EPS in 2024 and the firm sees earnings growth accelerating to double-digit in the second half of 24 and 2025, but its Neutral rating is based on intermediate term concerns over growth and the stock’s valuation, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on XYL: